APPROXIMATELY 40% of patients with diffuse large B-cell lymphoma (DLBCL) experience relapsed/refractory forms of the disease (R/R DLBCL). With effective forms of treatment currently lacking, there is an increasing need for the development of novel therapies to successfully treat the disease. This review provides a summary of the research presented by a panel of three experts at the virtual webcast symposium conference hosted by PeerVoice on 20th May 2021.
EMJ Hematology 9 [Supplement 6] . 2021
November 2021
In this issue
Latest articles
All articles![](https://www.emjreviews.com/wp-content/uploads/2024/04/Niamh-OConnell-Thumbnail-940x564.jpg)
![](https://www.emjreviews.com/wp-content/uploads/2024/03/Pier-Mannucci-940x564.png)
![](https://www.emjreviews.com/wp-content/uploads/2024/03/Immunoglobin-D-Multiple-Myeloma-940x564.png)
![](https://www.emjreviews.com/wp-content/uploads/2024/02/Coexistence-of-Sickle-Cell-Thalassaemia-with-Overlapping-Syndrome-940x564.png)